Compare Abbott Laboratories (ABT) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Kingsoft Cloud Holdings Limited — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Kingsoft Cloud Holdings Limited trades at $10.58 (market cap $2.80B). The key difference: Abbott Laboratories is far larger — about 59.6× Kingsoft Cloud Holdings Limited's market cap, and Abbott Laboratories pays a 2.63% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| ABT | KC | |
|---|---|---|
Market Cap | $166.94B | $2.80B |
Sector | Health | Technology |
52-Week High | $136.62 | $18.21 |
52-Week Low | $82.57 | $8.58 |
Enterprise Value | $193.69B | $3.11B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Kingsoft Cloud (KC) trades at $9.13 with a slight 0.33% daily gain, showing technical bearish signals despite recent earnings beats. The company reported $9.56B revenue for 2025 but continues to post net losses (-$936M), though AI-driven cloud demand is accelerating growth. Analyst sentiment remains positive with 70% buy ratings, while technical indicators show mixed signals with RSI levels suggesting potential oversold conditions.
KC presents a growth story fueled by AI cloud services expansion, but profitability challenges and negative margins create investor uncertainty. The stock's appeal hinges on management's ability to convert revenue growth into sustainable profits amid heavy infrastructure investments. Near-term catalysts include Q2 2026 earnings and margin improvement progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
